---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009697"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:42:58.230150+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed secures $50M upfront private placement; warrants could add $99.4M; funds Phase 2b DLB trial

## Summary
- Gross proceeds ~$50M upfront; up to ~$149.4M if Series A warrants ($39.24/share, 100% premium) fully exercised.
- Unit price $19.745; includes pre-funded warrants ($0.001 strike) and Series A warrants expiring Apr 2027 or post positive Phase 2b data.
- Financing led by RA Capital Management with Armistice, Special Situations, Soleus; Morgan Stanley and Canaccord placement agents.
- Net proceeds to fund neflamapimod R&D for dementia with Lewy bodies; expected cash runway through end of 2025.
- Closing expected April 1, 2024; resale registration statement to be filed within 60 days after close.

## SEC filing metadata
- accession: 0001437749-24-009697
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/0001437749-24-009697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/crvo20240326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009697
- JSON: https://secwatch.observer/filing/0001437749-24-009697.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009697.txt

## Key facts
- Material Agreements
  CervoMed Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $50 million (effective 2024-03-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: purchasers named therein
  - Value: approximately $50 million
  - Effective: 2024-03-28
  source text: On March 28, 2024, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 2,532,285 units
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/0001437749-24-009697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.